Literature DB >> 14718602

NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.

Yusheng Han1, Hongmei Shen, Brian I Carr, Peter Wipf, John S Lazo, Su-shu Pan.   

Abstract

Cdc25 dual-specificity phosphatases coordinate cell cycle progression and cellular signaling. Consequently, Cdc25 inhibitors represent potential anticancer agents. We evaluated >10,000 compounds for inhibition of human Cdc25 phosphatases and identified many potent and selective inhibitors, which all contained a quinone. Bioreductive enzymes frequently detoxify or activate quinones. Therefore, we evaluated the effect of NAD(P)H:quinone oxidoreductase-1 (NQO1) and reductase-rich microsomes on the activity of three quinone-containing Cdc25 inhibitors: 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone (Cpd 5, compound 5; NSC 672121), 2,3-bis-(2-hydroxyethylsulfanyl)-1,4-naphthoquinone (NSC 95397), and 6-chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione (NSC 663284). Each inhibitor was reduced by human NQO1 (K(m) of 0.3-0.5 microM) but none by microsomes. Compounds were evaluated with six cancer cell lines containing different amounts of NQO1: HT-29 (1056 nmol/mg/min), HCT116 (660 nmol/mg/min), sublines HCT116-R30A (28 nmol/mg/min) and HCT-116R30A/NQ5 (934 nmol/mg/min), MDA-MB-231/Q2 (null NQO1), and subline MDA-MB-231/Q6 (124 nmol/mg/min) but containing similar amounts of microsomal cytochrome P450 reductase and cytochrome b(5) reductase. Growth inhibition and G2/M arrest by Cpd 5 was proportional to NQO1 levels, requiring 4- to 5-fold more Cpd 5 to inhibit HCT-116 or HCT-116R30A/NQ5 compared with HCT-116R30A. In contrast, in all tested cell lines irrespective of NQO1 level, growth inhibition and G2/M arrest by NSC 95375 and NSC 663284 were similar (average IC(50) of 1.3 +/- 0.3 and 2.6 +/- 0.4 microM, respectively). NSC 95375 and NSC 663284 also caused similar Cdk1 hyperphosphorylation, indicating similar Cdc25 inhibition. However, lower Cpd 5 concentrations were needed to produce Cdk1 hyperphosphorylation in sublines with minimal NQO1. Thus, NQO1 detoxified Cpd 5, probably by reducing it to a less active hydroquinone, whereas NSC 95397- and NSC 663284-generated cytotoxicity was unaffected by NQO1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718602     DOI: 10.1124/jpet.103.059477

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

1.  Cysteine 81 is critical for the interaction of S100A4 and myosin-IIA.

Authors:  Natalya G Dulyaninova; Karen M Hite; Wendy D Zencheck; Dominic A Scudiero; Steven C Almo; Robert H Shoemaker; Anne R Bresnick
Journal:  Biochemistry       Date:  2011-07-21       Impact factor: 3.162

2.  Cdc25A Is a Critical Mediator of Ischemic Neuronal Death In Vitro and In Vivo.

Authors:  Grace O Iyirhiaro; Doo Soon Im; Wassamon Boonying; Steve M Callaghan; Matthew J During; Ruth S Slack; David S Park
Journal:  J Neurosci       Date:  2017-06-12       Impact factor: 6.167

3.  Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.

Authors:  Yakini Brandy; Innocent Ononiwu; Dolapo Adedeji; Vonetta Williams; Claudia Mouamba; Yasmine Kanaan; Robert L Copeland; Dwayne A Wright; Ray J Butcher; Samuel R Denmeade; Oladapo Bakare
Journal:  Invest New Drugs       Date:  2011-01-18       Impact factor: 3.850

Review 4.  Is Cdc25 a druggable target?

Authors:  John S Lazo; Peter Wipf
Journal:  Anticancer Agents Med Chem       Date:  2008-12       Impact factor: 2.505

5.  Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.

Authors:  Magdalena Zajac; Gonzalo Gomez; Javier Benitez; Beatriz Martínez-Delgado
Journal:  BMC Med Genomics       Date:  2010-10-04       Impact factor: 3.063

6.  Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.

Authors:  Andrea Vecchione; Gustavo Baldassarre; Hideshi Ishii; Milena S Nicoloso; Barbara Belletti; Fabio Petrocca; Nicola Zanesi; Louise Y Y Fong; Sabrina Battista; Daniela Guarnieri; Raffaele Baffa; Hansjuerg Alder; John L Farber; Peter J Donovan; Carlo M Croce
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

7.  Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease.

Authors:  Berta Canal; Ryo Fujisawa; Allison W McClure; Tom D Deegan; Mary Wu; Rachel Ulferts; Florian Weissmann; Lucy S Drury; Agustina P Bertolin; Jingkun Zeng; Rupert Beale; Michael Howell; Karim Labib; John F X Diffley
Journal:  Biochem J       Date:  2021-07-16       Impact factor: 3.857

8.  Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.

Authors:  Spencer B Hermanson; Coby B Carlson; Steven M Riddle; Jing Zhao; Kurt W Vogel; R Jeremy Nichols; Kun Bi
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

9.  Synthesis and characterization of novel unsymmetrical and symmetrical 3-halo- or 3-methoxy-substituted 2-dibenzoylamino-1,4-naphthoquinone derivatives.

Authors:  Yakini Brandy; Nailah Brandy; Emmanuel Akinboye; Malik Lewis; Claudia Mouamba; Seshat Mack; Ray J Butcher; Alan J Anderson; Oladapo Bakare
Journal:  Molecules       Date:  2013-02-04       Impact factor: 4.411

10.  Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo.

Authors:  Xinrui Yan; Mei-Sze Chua; Jing He; Samuel K So
Journal:  Mol Cancer       Date:  2008-02-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.